EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial

Kathryn E Beckermann iD, Aviva G Asnis-Alibozek, Michael B Atkins iD, Bernard Escudier, Thomas E Hutson, Vijay Kasturi, David F McDermott, Sumanta K Pal, Camillo Porta, Brian I Rini iD, Elena Verzoni

The Oncologist · 2024

DOI: 10.1093/oncolo/oyad348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Kathryn E Beckermann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Renal Cell, Kidney Neoplasms, Quinolines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AVEO Pharmaceuticals, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tivozanib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) with efficacy in advanced renal cell carcinoma (RCC). Long-term exploratory analyses from the TIVO-3 trial in relapsed/refractory (R/R) RCC including patients (26%) with prior immuno-oncology (IO) therapy are reported.

Methods

Patients with R/R advanced RCC that progressed with 2 or 3 prior systemic therapies (≥1 VEGFR TKI) were randomized to tivozanib 1.5 mg QD or sorafenib 400 mg BID, stratified by IMDC risk and previous therapy. Safety, investigator-assessed long-term progression-free survival (LT-PFS), and serial overall survival (OS) were assessed.

Results

Mean time on treatment was 11.0 months with tivozanib (n = 175) and 6.3 months with sorafenib (n = 175). Fewer grade ≥3 treatment-related adverse events occurred with tivozanib (46%) than sorafenib (55%). Dose modification rates were lower with tivozanib than sorafenib across age/prior IO subgroups; prior IO therapy did not impact dose reductions or discontinuations in either arm. Landmark LT-PFS rates were higher with tivozanib (3 years: 12.3% vs 2.4%; 4 years: 7.6% vs 0%). After 22.8 months mean follow-up, the OS HR was 0.89 (95% CI, 0.70-1.14); when conditioned on 12-month landmark PFS, tivozanib showed significant OS improvement over sorafenib (HR, 0.45; 95% CI, 0.22-0.91; 2-sided P = .0221).

Conclusions

Tivozanib demonstrated a consistent safety profile and long-term survival benefit in patients with R/R advanced RCC who were alive and progression free at 12 months. These post hoc exploratory analyses of LT-PFS and conditional OS support a clinically meaningful improvement with tivozanib versus sorafenib in this advanced RCC population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Renal CellKidney NeoplasmsQuinolinesHumansPhenylurea CompoundsProtein Kinase InhibitorsReceptors, Vascular Endothelial Growth FactorSorafenibVascular Endothelial Growth Factor AClinical Trials, Phase III as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

carcinomalong-term progression free survivalrelapsed kidney cancerrenal celltivozanibvascular endothelial growth factor

Substanzen

Antineoplastic AgentsPhenylurea CompoundsProtein Kinase InhibitorsQuinolinesReceptors, Vascular Endothelial Growth FactorSorafenibtivozanibVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Division of Hematology Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
  • Clinical Development and Medical Affairs, AVEO Oncology, Boston, MA, USA.
  • Department of Medical Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Department of Medical Oncology, Gustave Roussy, Villejuif, France.
  • Texas A&M College of Medicine, Bryan, TX, USA.
  • Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA, USA.

ORCID-Profile: Kathryn E Beckermann, Michael B Atkins, Brian I Rini

Förderung

  • AVEO Pharmaceuticals, Inc

Zitieren

APA

Beckermann, K. E., Asnis-Alibozek, A. G., Atkins, M. B., Escudier, B., Hutson, T. E., Kasturi, V., McDermott, D. F., Pal, S. K., Porta, C., Rini, B. I., & Verzoni, E. (2024). Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. The Oncologist. https://doi.org/10.1093/oncolo/oyad348

Vancouver

Beckermann KE, Asnis-Alibozek AG, Atkins MB, Escudier B, Hutson TE, Kasturi V, et al. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. The Oncologist. 2024. doi:10.1093/oncolo/oyad348

BibTeX
@article{Beckermann2024,
  author = {Beckermann, Kathryn E and Asnis-Alibozek, Aviva G and Atkins, Michael B and Escudier, Bernard and Hutson, Thomas E and Kasturi, Vijay and McDermott, David F and Pal, Sumanta K and Porta, Camillo and Rini, Brian I and Verzoni, Elena},
  title = {Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyad348}
}
Kostenlos starten →